New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, techno ...

A 70-year-old man presents with a chronic obstructive pulmonary disease (COPD) exacerbation. He reports shortness of breath and palpitations. He has no known heart disease but has experienced ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

Current recommendations for diagnosis of COPD in patients with respiratory symptoms require detection of airflow obstruction ...

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to ...

A US study found a significantly higher cost of care associated with cirrhosis vs with heart failure or chronic obstructive pulmonary disease.